JANSSEN PHARMACEUTICAL K.K.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Phase 3

Active, not recruiting

Conditions: Erythrodermic Psoriasis
Generalized Pustular Psoriasis

Interventions: Drug: JNJ-77242113

First Posted Date: 2024-03-06

Last Posted Date: 2024-12-06

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 19

Registration Number: NCT06295692

Locations: 🇯🇵
JR Sapporo Hospital, Hokkaido, Japan
🇯🇵
Ichinomiya Municipal Hospital, Ichinomiya, Japan
🇯🇵
Teikyo University Hospital, Itabashi Ku, Japan

and more 9 locations

A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa

Phase 3

Recruiting

Conditions: X-Linked Retinitis Pigmentosa

Interventions: Genetic: AAV5-hRKp.RPGR

First Posted Date: 2023-07-03

Last Posted Date: 2024-12-04

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 4

Registration Number: NCT05926583

Locations: 🇯🇵
National Hospital Organization Tokyo Medical Center, Meguro-ku, Japan

A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer

Phase 1

Recruiting

Conditions: Urinary Bladder Neoplasms
Receptors, Fibroblast Growth Factor

Interventions: Drug: Erdafitinib Intravesical Delivery System

First Posted Date: 2022-10-05

Last Posted Date: 2024-12-06

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 6

Registration Number: NCT05567185

Locations: 🇯🇵
Toyama University Hospital, Toyama-shi, Japan
🇯🇵
St Marianna University Hospital, Kanagawa, Japan
🇯🇵
Osaka International Cancer Institute, Osaka City, Japan

and more 1 locations

A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants

Phase 3

Terminated

Conditions: Respiratory Syncytial Virus Prevention

Interventions: Biological: Ad26/protein preF RSV Vaccine
Other: Placebo

First Posted Date: 2022-02-16

Last Posted Date: 2024-04-26

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 2192

Registration Number: NCT05242432

Locations: 🇯🇵
Clinical Research Hospital Tokyo, Shinjuku-ku, Japan
🇯🇵
Shinei Diabetes Clinic, Suginami-ku, Japan
🇯🇵
Ikebukuro Metropolitan Clinic, Tokyo-To, Japan

and more 27 locations

A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension

Phase 3

Active, not recruiting

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Macitentan

First Posted Date: 2021-12-22

Last Posted Date: 2024-12-06

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 7

Registration Number: NCT05167825

Locations: 🇯🇵
National Cerebral and Cardiovascular Center, Suita-Shi, Japan
🇯🇵
Osaka University Hospital, Suita-shi, Japan
🇯🇵
The University of Tokyo Hospital, Tokyo, Japan

and more 8 locations

A Study of JNJ-75105186 in Healthy Japanese and Chinese Participants

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: JNJ-75105186
Other: Placebo

First Posted Date: 2021-12-15

Last Posted Date: 2022-02-22

Lead Sponsor: Janssen Pharmaceutical K.K.

Registration Number: NCT05159128

Locations: 🇯🇵
Souseikai Fukuoka Mirai Hospital, Fukuoka-shi, Japan

A Study of JNJ-77242113 in Healthy Japanese and Chinese Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: JNJ-77242113
Drug: Placebo

First Posted Date: 2021-09-30

Last Posted Date: 2022-11-23

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 36

Registration Number: NCT05062200

Locations: 🇯🇵
Souseikai Hakata Clinic, Fukuoka, Japan

A Study of JNJ-75220795 in Japanese Participants

Phase 1

Terminated

Conditions: Fatty Liver

Interventions: Drug: JNJ-75220795
Other: Placebo

First Posted Date: 2021-09-09

Last Posted Date: 2023-05-16

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 9

Registration Number: NCT05039710

Locations: 🇯🇵
Souseikai Fukuoka Mirai Hospital, Fukuoka-shi, Japan
🇯🇵
Corporation Heishinkai OCROM Clinic, Suita-city, Japan
🇯🇵
Corporation Heishinkai ToCROM Clinic, Shinjuku-ku, Japan

and more 1 locations

A Study of Symptom Improvement of Ulcerative Colitis After an Induction Dose of Ustekinumab in Japanese Clinical Practice

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Ustekinumab

First Posted Date: 2021-07-15

Last Posted Date: 2024-01-03

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 137

Registration Number: NCT04963725

Locations: 🇯🇵
Shimane University Hospital, Izumo, Japan
🇯🇵
University Hospital Kyoto Perfectural University of Medicine, Kyoto, Japan
🇯🇵
Hamamatsu University Hospital, Hamamatsu, Japan

and more 20 locations

A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer

Phase 2

Terminated

Conditions: Stomach Neoplasms
Esophageal Neoplasms

Interventions: Drug: Amivantamab

First Posted Date: 2021-06-30

Last Posted Date: 2024-04-01

Lead Sponsor: Janssen Pharmaceutical K.K.

Target Recruit Count: 62

Registration Number: NCT04945733

Locations: 🇯🇵
National Cancer Center Hospital, Chuo Ku, Japan
🇯🇵
National Cancer Center Hospital East, Kashiwa, Japan
🇯🇵
Saitama Cancer center, Kitaadachi-gun, Japan

and more 7 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy